Mersana Therapeutics (NASDAQ:MRSN) issued its earnings results on Wednesday. The company reported ($0.35) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.37) by $0.02, Fidelity Earnings reports. The business had revenue of $0.84 million during the quarter, compared to analysts’ expectations of $0.50 million. Mersana Therapeutics had a negative net margin of 77.78% and a negative return on equity of 51.13%.
Mersana Therapeutics stock traded up $0.10 during midday trading on Friday, hitting $2.08. 184,700 shares of the stock were exchanged, compared to its average volume of 239,771. The stock’s 50-day simple moving average is $1.68 and its 200 day simple moving average is $3.30. The company has a current ratio of 5.50, a quick ratio of 5.50 and a debt-to-equity ratio of 0.06. Mersana Therapeutics has a fifty-two week low of $1.32 and a fifty-two week high of $7.65. The stock has a market capitalization of $88.45 million, a price-to-earnings ratio of -0.75 and a beta of 1.51.
MRSN has been the subject of a number of recent research reports. Zacks Investment Research upgraded shares of Mersana Therapeutics from a “sell” rating to a “hold” rating in a research report on Wednesday, October 23rd. ValuEngine upgraded shares of Mersana Therapeutics from a “hold” rating to a “buy” rating in a research report on Thursday, August 1st. Finally, HC Wainwright reiterated a “buy” rating and issued a $7.00 target price on shares of Mersana Therapeutics in a research report on Thursday. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating and five have issued a buy rating to the stock. Mersana Therapeutics currently has an average rating of “Buy” and an average price target of $7.83.
Mersana Therapeutics, Inc, a clinical stage biopharmaceutical company focusing on the development of antibody drug conjugate (ADC) for cancer patients with unmet need. The company develops Dolaflexin, a platform, which is used to generate a pipeline of proprietary ADC product candidates to address patient populations that are not amenable to treat with traditional ADC-based therapies.
Featured Article: 52 Week Highs
Receive News & Ratings for Mersana Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mersana Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.